251 related articles for article (PubMed ID: 31914336)
21. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
[TBL] [Abstract][Full Text] [Related]
23. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
Wang HL; Lu X; Yang X; Xu N
J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
[TBL] [Abstract][Full Text] [Related]
25. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Ueno T; Osawa M; Imai Y; Ishikawa H; Garimella T
J Clin Pharmacol; 2018 Nov; 58(11):1479-1488. PubMed ID: 30063245
[TBL] [Abstract][Full Text] [Related]
26. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
27. Asunaprevir for hepatitis C: a safety evaluation.
Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
[TBL] [Abstract][Full Text] [Related]
28. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
[TBL] [Abstract][Full Text] [Related]
29. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
[TBL] [Abstract][Full Text] [Related]
31. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
[TBL] [Abstract][Full Text] [Related]
33. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
[TBL] [Abstract][Full Text] [Related]
34. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
[TBL] [Abstract][Full Text] [Related]
36. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Lu Y; Jin X; Duan CA; Chang F
PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Osawa M; Ueno T; Shiozaki T; Ishikawa H; Li H; Garimella T
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):802-817. PubMed ID: 30629858
[TBL] [Abstract][Full Text] [Related]
40. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
